#South Korea #Seoul #Johnson & Johnson #LAZCLUZE #RYBREVANT FASPRO

Promising Results for RYBREVANT FASPRO and LAZCLUZE in Lung Cancer

At the 2026 World Conference on Lung Cancer (WCLC), Johnson & Johnson presented new findings from the Phase 2b COPERNICUS study. This study evaluated the combination of RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) and LAZCLUZE (lazertinib) for the treatment of advanced non-small cell lung cancer (NSCLC) among patients with EGFR mutations. The results revealed a significant advancement in treatment experiences, showcasing remarkably low rates of treatment-related events.

Key Findings

The COPERNICUS study aimed to reflect real-world clinical practices and involved a diverse group of participants enrolled across both academic and community sites. A key takeaway was that adverse events related to treatment were notably low, particularly with a less frequent dosing strategy combined with prophylactic care. Notably, fewer than 1% of patients discontinued treatment due to treatment-related events within a year.

Reduced Treatment-Related Adverse Events

The study highlighted specific adverse events, including rash, venous thromboembolism (VTE), and administration-related reactions (ARRs). Rash was reported in 25% of patients, with only 3% experiencing ARRs and VTEs. Importantly, no patients stopped treatment due to such reactions, and overall, only eight percent of participants discontinued the regimen owing to adverse events. This marks a significant improvement over previous studies, such as the Phase 3 MARIPOSA, where the rates of these adverse events were considerably higher.

Study Design and Accumulated Data

COPERNICUS is renowned for being one of the largest global studies focused on EGFR-mutated NSCLC, targeting an enrollment of 300 previously untreated patients. The participants averaged 67 years old, with a quarter aged 75 or older. The research team sought to ensure that this study design genuinely mirrored the day-to-day realities of healthcare delivery.

According to Dr. Balazs Halmos, a leading oncologist, these findings represent a vital evolution in how lung cancer treatment is approached, emphasizing patient experience and quality of life. The results reinforce the dual targeting mechanism of RYBREVANT, which blocks both EGFR and MET pathways that contribute to tumor growth and treatment resistance.

Future Implications

RYBREVANT FASPRO, which received FDA approval in late 2025, is noted for its formulation that offers injection options, allowing for once-monthly dosing after the initial weekly treatments. This system aims to streamline treatment and reduce patient burden. The combination with LAZCLUZE is already established to improve survival rates for patients with EGFR-mutant lung cancer, and the latest data further solidifies its role as a first-line treatment option for advanced NSCLC.

With Johnson & Johnson’s continuous commitment to enhance patient care, the insights gained from COPERNICUS will likely influence future clinical guidelines and treatment protocols aimed at improving patient outcomes. The study’s results continue to demonstrate the efficacy and safety of RYBREVANT FASPRO and LAZCLUZE, paving the way for treatment advancements in the battle against lung cancer.

Conclusion

The promising findings from the COPERNICUS study signal a hopeful shift in treating advanced NSCLC, ensuring better outcomes and improved quality of life for patients. By employing a thoughtful and innovative approach to treatment delivery, Johnson & Johnson is setting new standards in cancer care that prioritize both efficacy and patient experience.